bimosiamose-disodium and Inflammation

bimosiamose-disodium has been researched along with Inflammation* in 3 studies

Reviews

1 review(s) available for bimosiamose-disodium and Inflammation

ArticleYear
Targeting selectins for the treatment of respiratory diseases.
    Current opinion in investigational drugs (London, England : 2000), 2001, Volume: 2, Issue:7

    Inhibition of selectin function is expected to aid in the management of diseases characterized by aberrant or chronic inflammation, as in asthma and chronic obstructive pulmonary disease (COPD). Selectin-mediated adhesion of leukocytes to the vascular endothelium is a critical early event in the initiation of the inflammatory response, making it a good target for therapeutic intervention. Many approaches to modulating selectin function have been explored, including competitive inhibition, altering cell-surface expression and inducing shedding/cleavage from the cell surface; however, clinical success has been elusive.

    Topics: Animals; Anti-Asthmatic Agents; Asthma; Biphenyl Compounds; Cell Adhesion; Chemotaxis, Leukocyte; Clinical Trials as Topic; Endothelium, Vascular; Humans; Inflammation; Leukocytes; Ligands; Lung; Mannose; Mannosides; Membrane Glycoproteins; Oligosaccharides; Pulmonary Disease, Chronic Obstructive; Selectins; Sialyl Lewis X Antigen

2001

Other Studies

2 other study(ies) available for bimosiamose-disodium and Inflammation

ArticleYear
The anti-inflammatory effects of a selectin ligand mimetic, TBC-1269, are not a result of competitive inhibition of leukocyte rolling in vivo.
    Journal of leukocyte biology, 2005, Volume: 77, Issue:1

    Selectins and their ligands support leukocyte rolling, facilitating the subsequent firm adhesion and migration that occur during inflammation. TBC-1269 (Bimosiamose), a structural mimetic of natural selectin ligands, inhibits P-, E-, and L-selectin in vitro, has anti-inflammatory effects in vivo, and recently underwent phase II clinical trials for childhood asthma and psoriasis. We studied whether the anti-inflammatory effects of TBC-1269 could be related to leukocyte rolling in vivo. Although TBC-1269 inhibited rolling of a murine leukocyte cell line on murine P-selectin in vitro and thioglycollate-induced peritonitis in vivo, it did not alter leukocyte rolling in mouse cremaster venules. TBC-1269 reduced neutrophil recruitment in thioglycollate-induced peritonitis in wild-type and P-selectin-/- mice but not in E-selectin-/- mice. We suggest that the in vivo effects of TBC-1269 may be mediated through E-selectin but do not appear to involve leukocyte rolling.

    Topics: Animals; Binding, Competitive; Biphenyl Compounds; E-Selectin; Inflammation; Leukocytes; Ligands; Male; Mannose; Mannosides; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Knockout; Molecular Mimicry; Neutrophils; P-Selectin; Peptoids; Peritonitis; Thioglycolates; Venules

2005
Small-molecule selectin inhibitor protects against liver inflammatory response after ischemia and reperfusion.
    Journal of the American College of Surgeons, 1997, Volume: 185, Issue:4

    The selectin family of adhesion molecules plays a key role in the neutrophil-mediated injury observed after ischemia and reperfusion. In our study, we investigated the effects of TBC-1269, a novel small-molecule, nonoligosaccharide inhibitor of P-, E-, and L-selectin binding, in the liver inflammatory response after 90 minutes of warm ischemia.. Total liver ischemia was produced in Sprague-Dawley rats for 90 minutes using an extracorporeal portosystemic shunt. The animals were divided into five groups including: the sham (group 1), ischemic control (group 2) receiving only the vehicle, and the treated groups receiving TBC-1269 at a dose of 25 mg/kg at different times of administration: 15 minutes before reperfusion (group 3), at reperfusion (group 4), and 15 minutes after reperfusion (group 5). The following indices were analyzed: 7-day survival, liver injury tests, liver tissue myeloperoxidase as an index of neutrophil infiltration, and liver histology.. TBC-1269 treated groups experienced a significant increase in survival compared with controls. Best overall survival, 70%, was observed when TBC-1269 (Texas Biotechnology Corporation, Houston, TX) was administered 15 minutes before reperfusion (p < 0.05). This group also showed a marked decrease (p < 0.05) in liver enzyme levels at 6 hours after reperfusion. Neutrophil migration was also significantly ameliorated (81%), as reflected by decreased myeloperoxidase levels. We observed improved histologic damage scores in the treated group compared with controls (p < 0.05).. A small-molecule selectin inhibitor (TBC-1269) had a protective effect in livers subjected to 90 minutes of warm hepatic ischemia and 6 hours of reperfusion by decreasing neutrophil infiltration, migration and subsequent tissue damage. The best protective effect was achieved when the compound was administered 15 minutes before reperfusion. These findings offer a new therapeutic alternative for protection against ischemia and reperfusion injury.

    Topics: Animals; Antibodies, Monoclonal; Biphenyl Compounds; Disease Models, Animal; Inflammation; Liver; Mannose; Mannosides; Necrosis; Neutrophil Activation; Peroxidase; Rats; Rats, Sprague-Dawley; Reperfusion Injury; Selectins

1997